The Complex Tail of Circulating Sphingolipids in Atherosclerosis and Cardiovascular Disease

키워드

참고문헌 (115)

1. Saddoughi SA, "Diverse functions of ceramide in cancer cell death and proliferation", Adv Cancer Res, 117, pp.37~58 (2013)
2. Jensen SA, "Bcl2L13 is a ceramide synthase inhibitor in glioblastoma", Proc Natl Acad Sci U S A, 111, pp.5682~5687 (2014)
3. Mosbech MB, "Reduced ceramide synthase 2activity causes progressive myoclonic epilepsy", Ann Clin Transl Neurol, 1, pp.88~98 (2014)
4. Garić D, "Biochemistry of very-long-chain and longchain ceramides in cystic fibrosis and other diseases : the importance of side chain", Prog Lipid Res, 74, pp.130~144 (2019)
5. Summers SA, "Metabolic messengers : ceramides", Nat Metab, 1, pp.1051~1058 (2019)
6. Peterson LR, "Ceramide remodeling and risk of cardiovascular events and mortality", J Am Heart Assoc, 7, pp.e007931~ (2018)
7. Yu J, "Ceramide is upregulated and associated with mortality in patients with chronic heart failure", Can J Cardiol, 31, pp.357~363 (2015)
8. Laaksonen R, "Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol", Eur Heart J, 37, pp.1967~1976 (2016)
9. Li Q, "Associations between plasma ceramides and mortality in patients with coronary artery disease", Atherosclerosis, 314, pp.77~83 (2020)
10. Raichur S, "Ceramide synthases are attractive drug targets for treating metabolic diseases", Front Endocrinol(Lausanne), 11, pp.483~ (2020)
11. Yu Z, "Potential therapeutic targets for atherosclerosis in sphingolipid metabolism", Clin Sci(Lond), 133, pp.763~776 (2019)
12. Futerman AH, "Biochemistry of lipids, lipoproteins and membranes", pp.97~326, Elsevier
13. Hannun YA, "Principles of bioactive lipid signalling : lessons from sphingolipids", Nat Rev Mol Cell Biol, 9, pp.139~150 (2008)
14. Zelnik ID, "A stroll down the CerS lane", Adv Exp Med Biol, 1159, pp.49~63 (2019)
15. Ferreira NS, "Regulation of very-long acyl chain ceramide synthesis by acyl-CoA-binding protein", J Biol Chem, 292, pp.7588~7597 (2017)
16. van Meer G, "Cellular lipidomics", EMBO J, 24, pp.3159~3165 (2005)
17. Merrill AH Jr, "Sphingolipidomics : high-throughput, structurespecific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry", Methods, 36, pp.207~224 (2005)
18. Tidhar R, "The complexity of sphingolipid biosynthesis in the endoplasmic reticulum", Biochim Biophys Acta, 1833, pp.2511~2518 (2013)
19. Laviad EL, "Characterization of ceramide synthase 2 : tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate", J Biol Chem, 283, pp.5677~5684 (2008)
20. Laviad EL, "Modulation of ceramide synthase activity via dimerization", J Biol Chem, 287, pp.21025~21033 (2012)
21. Sassa T, "Enzyme activities of the ceramide synthases CERS2-6 are regulated by phosphorylation in the C-terminal region", J Biol Chem, 291, pp.7477~7487 (2016)
22. Zhang W, "Fatty acid transporting proteins : Roles in brain development, aging, and stroke", Prostaglandins Leukot Essent Fatty Acids, 136, pp.35~45 (2018)
23. Watkins PA, "Fatty acid activation", Prog Lipid Res, 36, pp.55~83 (1997)
24. Suzuki H, "Structure and regulation of rat long-chain acyl-CoA synthetase", J Biol Chem, 265, pp.8681~8685 (1990)
25. Schaffer JE, "Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein", Cell, 79, pp.427~436 (1994)
26. Hunt MC, "The emerging role of acyl-CoA thioesterases and acyltransferases in regulating peroxisomal lipid metabolism", Biochim Biophys Acta, 1822, pp.1397~1410 (2012)
27. Senkal CE, "ceramide is metabolized to acylceramide and stored in lipid droplets", Cell Metab, 25, pp.686~697 (2017)
28. Grevengoed TJ, "Acyl-CoA metabolism and partitioning", Annu Rev Nutr, 34, pp.1~30 (2014)
29. Igal RA, "Triacsin C blocks de novo synthesis of glycerolipids and cholesterol esters but not recycling of fatty acid into phospholipid : evidence for functionally separate pools of acyl-CoA", Biochem J, 324, pp.529~534 (1997)
30. Bowden JA, "Harmonizing lipidomics : NIST interlaboratory comparison exercise for lipidomics using SRM 1950-metabolites in frozen human plasma", J Lipid Res, 58, pp.2275~2288 (2017)
31. Hammad SM, "Blood sphingolipidomics in healthy humans : impact of sample collection methodology", J Lipid Res, 51, pp.3074~3087 (2010)
32. Hammad SM, "Sphingosine 1-phosphate distribution in human plasma : associations with lipid profiles", J Lipids, 2012, pp.180705~ (2012)
33. Wang X, "Sphingolipids in food and their critical roles in human health", Crit Rev Food Sci Nutr, 61, pp.462~491 (2020)
34. Kaur N, "Essential fatty acids as functional components of foods-a review", J Food Sci Technol, 51, pp.2289~2303 (2014)
35. Vesper H, "Sphingolipids in food and the emerging importance of sphingolipids to nutrition", J Nutr, 129, pp.1239~1250 (1999)
36. Yunoki K, "Analysis of sphingolipid classes and their contents in meals", Biosci Biotechnol Biochem, 72, pp.222~225 (2008)
37. Ueda O, "Distribution in skin of ceramide after oral administration to rats", Drug Metab Pharmacokinet, 24, pp.180~184 (2009)
38. Ueda O, "Distribution and metabolism of sphingosine in skin after oral administration to mice", Drug Metab Pharmacokinet, 25, pp.456~465 (2010)
39. Nilsson A, "Metabolism of sphingomyelin in the intestinal tract of the rat", Biochim Biophys Acta, 164, pp.575~584 (1968)
40. Nilsson A, "Metabolism of cerebroside in the intestinal tract of the rat", Biochim Biophys Acta, 187, pp.113~121 (1969)
41. Nilsson A, "The presence of spingomyelin-and ceramide-cleaving enzymes in the small intestinal tract", Biochim Biophys Acta, 176, pp.339~347 (1969)
42. Schmelz EM, "Uptake and metabolism of sphingolipids in isolated intestinal loops of mice", J Nutr, 124, pp.702~712 (1994)
43. Nyberg L, "Identification of an alkaline sphingomyelinase activity in human bile", Biochim Biophys Acta, 1300, pp.42~48 (1996)
44. Chung RW, "Effect of long-term dietary sphingomyelin supplementation on atherosclerosis in mice", PLoS One, 12, pp.e0189523~ (2017)
45. Duan RD, "Distribution of alkaline sphingomyelinase activity in human beings and animals. Tissue and species differences", Dig Dis Sci, 41, pp.1801~1806 (1996)
46. Chen H, "Sphingomyelin content of intestinal cell membranes regulates cholesterol absorption. Evidence for pancreatic and intestinal cell sphingomyelinase activity", Biochem J, 286, pp.771~777 (1992)
47. Fukami H, "Preparation of(13)C-labeled ceramide by acetic acid bacteria and its incorporation in mice", J Lipid Res, 51, pp.3389~3395 (2010)
48. Ishikawa J, "Dietary glucosylceramide is absorbed into the lymph and increases levels of epidermal sphingolipids", J Dermatol Sci, 56, pp.216~218 (2009)
49. Sugawara T, "Intestinal absorption of dietary maize glucosylceramide in lymphatic duct cannulated rats", J Lipid Res, 51, pp.1761~1769 (2010)
50. Li Z, "The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis", Biochim Biophys Acta, 1735, pp.130~134 (2005)
51. Ribel-Madsen A, "Plasma ceramide levels are altered in low and normal birth weight men in response to short-term high-fat overfeeding", Sci Rep, 8, pp.3452~ (2018)
52. Merrill AH Jr, "Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion", J Biol Chem, 270, pp.13834~13841 (1995)
53. Murata N, "Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions", Biochem J, 352, pp.809~815 (2000)
54. Gruffat D, "Regulation of VLDL synthesis and secretion in the liver", Reprod Nutr Dev, 36, pp.375~389 (1996)
55. Ågren JJ, "Isolation of very low density lipoprotein phospholipids enriched in ethanolamine phospholipids from rats injected with Triton WR 1339", Biochim Biophys Acta, 1734, pp.34~43 (2005)
56. Iqbal J, "Microsomal triglyceride transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but not glycosylceramide", J Biol Chem, 290, pp.25863~25875 (2015)
57. Yang LY, "Surface components of chylomicrons from rats fed glyceryl or alkyl esters of fatty acids : minor components", Lipids, 27, pp.613~618 (1992)
58. Frostegård J, "Immunity, atherosclerosis and cardiovascular disease", BMC Med, 11, pp.117~ (2013)
59. Murphy SL, "Deaths : final Data for 2018", Natl Vital Stat Rep, 69, pp.1~83 (2021)
60. Bentzon JF, "Mechanisms of plaque formation and rupture", Circ Res, 114, pp.1852~1866 (2014)
61. Libby P, "Progress and challenges in translating the biology of atherosclerosis", Nature, 473, pp.317~325 (2011)
62. Smith EB, "Intimal and medial lipids in human aortas", Lancet, 1, pp.799~803 (1960)
63. Edsfeldt A, "Sphingolipids contribute to human atherosclerotic plaque inflammation", Arterioscler Thromb Vasc Biol, 36, pp.1132~1140 (2016)
64. Rapp JH, "Lipids of human atherosclerotic plaques and xanthomas : clues to the mechanism of plaque progression", J Lipid Res, 24, pp.1329~1335 (1983)
65. Wu M, "Specific imaging of atherosclerotic plaque lipids with two-wavelength intravascular photoacoustics", Biomed Opt Express, 6, pp.3276~3286 (2015)
66. Ross R, "The pathogenesis of atherosclerosis : a perspective for the 1990s", Nature, 362, pp.801~809 (1993)
67. Havel RJ, "Biology of cholesterol, lipoproteins and atherosclerosis", Clin Exp Hypertens A, 11, pp.887~900 (1989)
68. Keys A, "Alpha lipoprotein(HDL)cholesterol in the serum and the risk of coronary heart disease and death", Lancet, 316, pp.603~606 (1980)
69. Keys A, "Coronary heart disease, serum cholesterol, and the diet", Acta Med Scand, 207, pp.153~160 (1980)
70. Sachdeva A, "Lipid levels in patients hospitalized with coronary artery disease : an analysis of 136, 905 hospitalizations in Get With The Guidelines", Am Heart J, 157, pp.111~117 (2009)
71. Stegemann C, "Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study", Circulation, 129, pp.1821~1831 (2014)
72. Didangelos A, "The-omics era : proteomics and lipidomics in vascular research", Atherosclerosis, 221, pp.12~17 (2012)
73. "Institute of Medicine. Promoting cardiovascular health in the developing world" (2010), The National Academies Press
74. Puig N, "Search for reliable circulating biomarkers to predict carotid plaque vulnerability", Int J Mol Sci, 21, pp.8236~ (2020)
75. Sullards MC, "Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry", Sci STKE, 2001;2001, pp.pl1~ (2001)
76. Sullards MC, "Analysis of mammalian sphingolipids by liquid chromatography tandem mass spectrometry(LC-MS", MS)and tissue imaging mass spectrometry(TIMS), 2011, pp.1811, 838~853
77. Fernandez C, "Plasma lipid composition and risk of developing cardiovascular disease", PLoS One, 8, pp.e71846~ (2013)
78. Havulinna AS, "Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort", Arterioscler Thromb Vasc Biol, 36, pp.2424~2430 (2016)
79. Jiang XC, "Plasma sphingomyelin level as a risk factor for coronary artery disease", Arterioscler Thromb Vasc Biol, 20, pp.2614~2618 (2000)
80. Schissel SL, "Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins", J Clin Invest, 98, pp.1455~1464 (1996)
81. Ichi I, "Association of ceramides in human plasma with risk factors of atherosclerosis", Lipids, 41, pp.859~863 (2006)
82. Pan W, "Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes", Coron Artery Dis, 25, pp.230~235 (2014)
83. Holopainen JM, "Sphingomyelinase activity associated with human plasma low density lipoprotein", J Biol Chem, 275, pp.16484~16489 (2000)
84. Marathe S, "Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix", Arterioscler Thromb Vasc Biol, 19, pp.2648~2658 (1999)
85. Marathe S, "Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling", J Biol Chem, 273, pp.4081~4088 (1998)
86. Schissel SL, "Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development", J Biol Chem, 273, pp.2738~2746 (1998)
87. Kinscherf R, "Modified low density lipoprotein delivers substrate for ceramide formation and stimulates the sphingomyelin-ceramide pathway in human macrophages", FEBS Lett, 405, pp.55~59 (1997)
88. Marathe S, "Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent inducers of macrophage foam cell formation", Arterioscler Thromb Vasc Biol, 20, pp.2607~2613 (2000)
89. Xu XX, "Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages", J Biol Chem, 266, pp.24849~24858 (1991)
90. Ruuth M, "Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths", Eur Heart J, 39, pp.2562~2573 (2018)
91. Morita SY, "Ceramide in lipid particles enhances heparan sulfate proteoglycan and low density lipoprotein receptor-related protein-mediated uptake by macrophages", J Biol Chem, 279, pp.24355~24361 (2004)
92. Morita SY, "Formation of ceramide-enriched domains in lipid particles enhances the binding of apolipoprotein E", FEBS Lett, 579, pp.1759~1764 (2005)
93. Oörni K, "Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein(LDL)particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans", J Biol Chem, 273, pp.29127~29134 (1998)
94. Sneck M, "Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH", J Lipid Res, 53, pp.1832~1839 (2012)
95. Benitez-Amaro A, "Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1(LRP1)-derived peptides against LDL aggregation", Biochim Biophys Acta Biomembr, 1861, pp.1302~1316 (2019)
96. Augé N, "The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation", J Biol Chem, 271, pp.19251~19255 (1996)
97. Zelnik ID, "The role of ceramide in regulating endoplasmic reticulum function", Biochim Biophys Acta Mol Cell Biol Lipids, 1865, pp.158489~ (2020)
98. Hojjati MR, "Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice", J Biol Chem, 80, pp.10284~10289 (2005)
99. Park TS, "Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice", Circulation, 110, pp.3465~3471 (2004)
100. Kasumov T, "Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis", PLoS One, 10, pp.e0126910~ (2015)
101. Cirillo F, "The antithetic role of ceramide and sphingosine-1-phosphate in cardiac dysfunction", J Cell Physiol, 236, pp.4857~4873 (2021)
102. Mahley RW, "Remnant lipoprotein metabolism : key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E", J Lipid Res, 40, pp.1~16 (1999)
103. Li Y, "Progression of atherosclerosis in ApoE-knockout mice fed on a highfat diet", Eur Rev Med Pharmacol Sci, 20, pp.3863~3867 (2016)
104. Tarasov K, "Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency", J Clin Endocrinol Metab, 99, pp.E45~ (2014)
105. Cheng JM, "Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome : Results of the ATHEROREMO-IVUS study", Atherosclerosis, 243, pp.560~566 (2015)
106. Saleem M, "Association between sphingolipids and cardiopulmonary fitness in coronary artery disease patients undertaking cardiac rehabilitation", J Gerontol A Biol Sci Med Sci, 75, pp.671~679 (2020)
107. Ding M, "A review of lipidomics of cardiovascular disease highlights the importance of isolating lipoproteins", Metabolites, 10, pp.163~ (2020)
108. Alshehry ZH, "Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in Type 2 diabetes mellitus", Circulation, 134, pp.1637~1650 (2016)
109. Mundra PA, "Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention", JCI Insight, 3, pp.e121326~ (2018)
110. Poss AM, "Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease", J Clin Invest, 130, pp.1363~1376 (2020)
111. Tu C, "Association between ceramides and coronary artery stenosis in patients with coronary artery disease", Lipids Health Dis, 19, pp.151~ (2020)
112. Nicholls M, "Plasma ceramides and cardiac risk", Eur Heart J, 38, pp.1359~1360 (2017)
113. Mullen TD, "Ceramide synthases at the centre of sphingolipid metabolism and biology", Biochem J, 441, pp.789~802 (2012)
114. Pewzner-Jung Y, "When do Lasses(longevity assurance genes)become CerS(ceramide synthases)? : insights into the regulation of ceramide synthesis", J Biol Chem, 281, pp.25001~25005 (2006)
115. Kitatani K, "The sphingolipid salvage pathway in ceramide metabolism and signaling", Cell Signal, 20, pp.1010~1018 (2008)

관련 논문AI추천